GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETV) » Definitions » Debt-to-EBITDA

PetVivo Holdings (PetVivo Holdings) Debt-to-EBITDA : -0.20 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is PetVivo Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PetVivo Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.33 Mil. PetVivo Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.07 Mil. PetVivo Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was $-6.87 Mil. PetVivo Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.20.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PetVivo Holdings's Debt-to-EBITDA or its related term are showing as below:

PETV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.39   Med: -0.07   Max: -0.03
Current: -0.13

During the past 13 years, the highest Debt-to-EBITDA Ratio of PetVivo Holdings was -0.03. The lowest was -0.39. And the median was -0.07.

PETV's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs PETV: -0.13

PetVivo Holdings Debt-to-EBITDA Historical Data

The historical data trend for PetVivo Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetVivo Holdings Debt-to-EBITDA Chart

PetVivo Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.34 -0.39 -0.07 -0.04

PetVivo Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.04 -0.12 -0.09 -0.20

Competitive Comparison of PetVivo Holdings's Debt-to-EBITDA

For the Medical Devices subindustry, PetVivo Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetVivo Holdings's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PetVivo Holdings's Debt-to-EBITDA falls into.



PetVivo Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PetVivo Holdings's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.085 + 0.26) / -8.619
=-0.04

PetVivo Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.326 + 1.073) / -6.868
=-0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


PetVivo Holdings  (OTCPK:PETV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


PetVivo Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PetVivo Holdings (PetVivo Holdings) Business Description

Traded in Other Exchanges
N/A
Address
5251 Edina Industrial Boulevard, Edina, MN, USA, 55439
PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.
Executives
James Rudolph Martin director POBOX 53988, IRVINE CA 92619
A.l. Sarroff Fund, Llc 10 percent owner 43 MEADOW WOODS ROAD, GREAT NECK NY 11020
John Spencer Breithaupt director 3041 W. PASADENA DR., BOISE ID 83705
Robert J Costantino director 5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Joseph William Jasper director 201 SOUTH 11TH STREET, UNIT 1030, MINNEAPOLIS MN 55403
John Lai director, 10 percent owner, officer: CEO 12100 SINGLETREE LANE, SUITE 186, EDEN PRAIRIE MN 55344
Robert James Rudelius director 6913 ARBOR LANE, MCCLEAN VA 22101
Leslie Anne Coolidge director 345 OLD SUTTON ROAD, BARRINGTON HILLS IL 60010
Robert J. Folkes officer: Chief Financial Officer 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Scott Mitchell Johnson director 475 LAKESHORE UNIT #32, INCLINE VILLAGE NV 89451
James Joseph Martin director 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Gregory D Cash director
John Michael Carruth officer: Acting Chief Financial Officer 4923 RIVER WOOD DR., SAVAGE MN 55439
Sherry Grisewood director 377 FAIRMOUNT ROAD, CALIFON NJ 07830
David Don Deming director 16200 45TH STREET SOUTH, AFTON MN 55001

PetVivo Holdings (PetVivo Holdings) Headlines

From GuruFocus

Spencer Breithaupt Joins PetVivo Holdings, Inc. Board of Directors

By sperokesalga sperokesalga 04-14-2023